Loading…
3B Blackbio Dx (3BBLACKBIO)₹1,294+1.39%Healthcare Service Provider
In the Jun 2026 quarter (consolidated), 3B Blackbio Dx reported sales of ₹33.43 Cr, up 50.6% from Jun 2025, and net profit of ₹8.97 Cr, down 29.1% year on year. For the year to Mar 2026, sales were ₹142 Cr and net profit ₹59.99 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.16 | 17.66 | 22.96 | 19.39 | 29.12 | 25.37 | 22.48 | 22.20 | 33.85 | 50.28 | 35.38 | 33.43 |
| Expenses | 11.42 | 8.82 | 13.18 | 8.52 | 13.03 | 10.35 | 14.63 | 10.43 | 19.24 | 28.72 | 27.03 | 25.06 |
| Operating Profit | 7.80 | 8.88 | 9.89 | 10.94 | 16.18 | 15.08 | 7.93 | 11.84 | 14.72 | 21.71 | 8.48 | 8.51 |
| OPM % | 40.6% | 50.3% | 43.0% | 56.4% | 55.5% | 59.4% | 35.2% | 53.3% | 43.5% | 43.2% | 24.0% | 25.5% |
| Other Income | 2.74 | 2.62 | 4.18 | 3.68 | 3.43 | 3.00 | 4.93 | 4.31 | 5.50 | 5.58 | 10.14 | 6.13 |
| Interest | 0.05 | 0.04 | 0.05 | 0.02 | 0.04 | 0.03 | 0.05 | 0.02 | 0.05 | 0.10 | 0.11 | 0.11 |
| Depreciation | 0.25 | 0.33 | 0.31 | 0.28 | 0.28 | 0.28 | 0.29 | 0.29 | 0.59 | 0.39 | 3.90 | 1.35 |
| Profit before tax | 10.27 | 11.17 | 13.74 | 14.38 | 19.33 | 17.82 | 12.55 | 15.90 | 19.66 | 26.90 | 14.66 | 13.25 |
| Tax % | 26.1% | 23.7% | 36.0% | 21.3% | 23.0% | 24.2% | 35.9% | 20.3% | 23.4% | 16.4% | 33.2% | 32.1% |
| Net Profit | 7.57 | 8.52 | 8.78 | 11.29 | 14.88 | 13.48 | 8.05 | 12.66 | 15.05 | 22.45 | 9.80 | 8.97 |
| EPS (Rs) | 10.48 | 10.18 | 10.35 | 13.00 | 17.10 | 15.65 | 9.81 | 14.70 | 17.19 | 25.36 | 11.17 | 11.12 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.96 | 15.98 | 22.96 | 22.96 | 28.98 | 227 | 80.92 | 61.92 | 73.87 | 95.90 | 142 | 153 |
| Expenses | 16.07 | 14.05 | 18.06 | 16.06 | 20.07 | 77.25 | 44.16 | 33.13 | 41.18 | 46.17 | 85.27 | 100 |
| Operating Profit | 2.01 | 3.01 | 5.01 | 7.01 | 9.01 | 150 | 37.01 | 28.99 | 33.01 | 50.01 | 56.97 | 53.42 |
| OPM % | 9.0% | 16.0% | 23.0% | 31.1% | 32.0% | 66.1% | 46.0% | 47.0% | 44.1% | 52.0% | 40.0% | 34.9% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.99 | 1.99 | 2.99 | 6.99 | 6.99 | 12.99 | 14.98 | 25.98 | 27.35 |
| Interest | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.37 |
| Depreciation | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 5.01 | 6.23 |
| Profit before tax | 0.00 | 1.01 | 5.01 | 7.01 | 10.02 | 152 | 43.03 | 35.05 | 44.04 | 64.05 | 77.08 | 74.47 |
| Tax % | 23.0% | 19.0% | 24.0% | 25.0% | 23.0% | 25.0% | 26.0% | 27.0% | 28.0% | 25.0% | 22.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.99 | 3.01 | 4.99 | 8.01 | 114 | 32.02 | 26.01 | 31.98 | 48.04 | 59.99 | 56.27 |
| EPS (Rs) | 0.52 | 1.77 | 5.36 | 8.20 | 10.26 | 152.08 | 42.96 | 34.60 | 37.46 | 55.68 | 68.44 | 64.84 |
| Dividend payout % | 0.0% | 17.1% | 9.0% | 6.0% | 7.1% | 6.0% | 24.1% | 8.0% | 8.0% | 7.0% | 7.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.99 | 5.99 | 5.99 | 6.00 | 6.00 | 7.01 | 7.01 | 7.01 | 9.01 | 9.02 | 9.02 | 9.02 |
| Reserves | 3.99 | 3.99 | 4.98 | 11.95 | 15.95 | 24.91 | 125 | 146 | 185 | 214 | 260 | 315 |
| Borrowings | 8.00 | 7.99 | 8.99 | 6.01 | 6.00 | 4.01 | 2.01 | 3.01 | 2.01 | 1.01 | 0.00 | 3.01 |
| Other Liabilities | 6.96 | 5.97 | 5.97 | 5.97 | 7.96 | 8.97 | 58.99 | 37.18 | 19.08 | 24.11 | 27.13 | 51.25 |
| Total Liabilities | 24.94 | 23.94 | 25.93 | 29.93 | 35.91 | 44.90 | 194 | 192 | 214 | 248 | 296 | 378 |
| Fixed Assets | 4.01 | 3.01 | 3.01 | 4.01 | 4.01 | 4.01 | 5.01 | 7.01 | 8.01 | 7.01 | 7.01 | 28.03 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 59.14 | 93.23 | 92.14 | 117 | 156 | 158 |
| Other Assets | 20.93 | 20.93 | 21.92 | 25.92 | 31.90 | 39.88 | 129 | 92.60 | 114 | 123 | 132 | 192 |
| Inventories | 3.99 | 2.99 | 3.99 | 3.99 | 4.99 | 3.98 | 4.98 | 6.98 | 7.98 | 7.97 | 8.97 | 17.95 |
| Trade receivables | 13.98 | 12.99 | 13.99 | 15.98 | 17.97 | 19.97 | 34.93 | 29.95 | 33.94 | 35.96 | 36.95 | 49.93 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 1.99 | 2.99 | 8.99 | 34.99 | 28.97 | 58.96 | 61.95 | 68.89 | 101 |
| Total Assets | 24.94 | 23.94 | 25.93 | 29.93 | 35.91 | 44.90 | 194 | 192 | 214 | 248 | 296 | 378 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | 0.99 | 0.99 | 1.99 | 3.99 | 6.99 | 97.76 | 36.89 | 19.94 | 26.92 | 42.90 | 51.84 |
| Cash from investing activity | — | 0.00 | 0.00 | −0.99 | −0.99 | −0.99 | −69.91 | −27.97 | 14.96 | −19.98 | −32.93 | −23.96 |
| Cash from financing activity | — | −1.01 | 0.00 | 0.00 | −1.01 | 1.01 | −2.01 | −15.04 | −5.01 | −4.01 | −3.01 | −1.01 |
| Net cash flow | — | 0.00 | 0.00 | 0.99 | 1.99 | 6.99 | 25.98 | −5.99 | 29.95 | 2.99 | 6.99 | 27.97 |
| Capex | 0.01 | 0.29 | 0.30 | 1.02 | 0.71 | 0.53 | 1.67 | 2.25 | 2.01 | 0.50 | 0.89 | 25.47 |
| Free cash flow | — | 0.99 | 0.00 | 0.99 | 2.99 | 5.99 | 95.90 | 34.98 | 17.97 | 25.97 | 41.93 | 26.96 |
| CFO / OP % | — | 69.0% | 36.1% | 52.1% | 71.0% | 101.1% | 90.0% | 129.0% | 100.1% | 115.0% | 116.0% | 121.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 261 | 282 | 320 | 258 | 289 | 251 | 55 | 135 | 199 | 178 | 137 | 128 |
| Inventory days | 144 | 142 | 174 | — | — | — | — | — | 163 | 140 | 123 | 186 |
| Days payable | 218 | 203 | 186 | — | — | — | — | — | 69 | 66 | 28 | 70 |
| Cash conversion cycle | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 | 235 | 245 |
| Working capital days | 175 | 205 | 247 | 253 | 287 | 275 | 65 | 162 | 241 | 215 | 169 | 143 |
| ROCE % | 7.0% | 7.0% | 13.0% | 23.9% | 28.0% | 31.0% | 162.0% | 26.9% | 19.0% | 20.9% | 26.0% | 24.9% |
For the Jun 2026 quarter, 3B Blackbio Dx reported sales of ₹33.43 Cr, up 50.6% year on year and net profit of ₹8.97 Cr, down 29.1% year on year. The operating margin was 25.5%.
3B Blackbio Dx's sales for the year to Mar 2026 were ₹142 Cr; over the last twelve months they were ₹153 Cr.
Net profit for the year to Mar 2026 was ₹59.99 Cr, and ₹56.27 Cr over the last twelve months. Earnings per share over the same trailing period were ₹64.84.
3B Blackbio Dx reported borrowings of ₹3.01 Cr at Mar 2026, against cash and equivalents of ₹101 Cr.
Cash from operations was ₹51.84 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹26.96 Cr.